PR90368

BRUSSELS and CASTRES, France, June 29, 2021 /PRNewswire=KYODO JBN/ --

- Partnership builds on complementary strengths to advance research in melanoma

with a focus on Stage 2 melanoma patients

European Organisation for Research and Treatment of Cancer (EORTC) and Pierre

Fabre today announced a strategic partnership in support of patients with

resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning,

design and execution of a large Phase 3 study investigating the use of BRAF and

MEK targeted therapies to reduce the risk of relapse in this patient

population, currently under approval with authorities.

"Sadly, still today too many patients with Stage 2 melanoma have their cancer

come back, even after their tumour is removed. Further understanding how

effective treatments can have an impact on recurrence is essential," said Dr

Denis Lacombe, CEO of EORTC. "We are pleased to collaborate with Pierre Fabre

who bring strong heritage and expertise in this therapeutic area, to make a

true difference to people living with Stage 2 melanoma."

"Collaboration between Pierre Fabre and EORTC is the perfect match between our

medical and clinical capabilities and a leading global network in oncology

research. Our strong complementary expertise have potential to transform

patient care in melanoma," said Dr Deborah Szafir, EVP, Head of Medical and

Patient Centricity Division at Pierre Fabre. "Our strategic partnership on a

pioneering Phase 3 study confirms Pierre Fabre's R&D commitment to oncology and

particularly in skin cancers. Through our growing expertise in BRAF and MEK

inhibitors, we aim to strengthen our support for patients with skin cancers."

Pierre Fabre has a long-standing commitment to the melanoma community and takes

a unique holistic approach to skin health through combined expertise in

oncology, dermatology, and dermo-cosmetics. EORTC, a network uniting 2,800

clinical cancer research experts across the globe, shares Pierre Fabre's

commitment to improving the standard of cancer treatment for patients.

For further information, please visit the EORTC website (www.eortc.org) and the

Pierre Fabre website (www.pierre-fabre.com) - @PierreFabre.

References

1. Neoplasma. 2016;63(4):510-7. doi: 10.4149/neo_2016_403.

2. American Cancer Society. What Causes Melanoma Skin Cancer. Available at:

https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-prevention/what-causes.html.

Accessed June 2021.

3. International Agency for Research on Cancer. Melanoma of skin. Available at:

https://gco.iarc.fr/today/data/factsheets/cancers/16-Melanoma-of-skin-fact-sheet.pdf.

Accessed June 2021.

4. Klein O, et al. Eur J Cancer 2013;49:1073–1079.

5. Melanoma UK. 2020 Melanoma Skin Cancer Report. Available at:

https://www.melanomauk.org.uk/2020-melanoma-skin-cancer-report. Accessed June

2021.

Logo - https://mma.prnewswire.com/media/1553958/EORTC_Pierre_Fabre_Logo.jpg

Contacts:

EORTC:

Isabelle Gautherot

communication@eortc.org

Pierre Fabre:

Anne Kerveillant

anne.kerveillant@pierre-fabre.com

Source: EORTC and Pierre Fabre